Arcturus Therapeutics Holdings Inc. (ARCT) Balance Sheet

This consistent asset erosion signals a company in a defined spending phase, where the balance sheet is being systematically deployed to advance its pipeline. The trajectory is sustainable only if the underlying science generates material, non-dilutive capital inflows before the cash base is depleted, which current revenue trends do not suggest.

The high current ratio is a function of low current liabilities relative to a large, albeit diminishing, cash balance. This is not a liquidity crisis but a capital adequacy question; the critical variable is the quarterly burn rate, which the prior cash flow analysis indicates is accelerating, directly compressing the company's operational runway.

This massive accumulated deficit is a stark visual of the company's long-term, pre-revenue investment profile. It underscores that current book value is a function of recent equity issuances and is not a reflection of value creation to date; future equity value is entirely contingent on pipeline commercialization success.

The modest and stable debt load indicates the company is funding its operations primarily through equity and cash reserves. This conservative structure minimizes near-term refinancing risk but also implies that if the cash runway shortens, the company may need to access debt markets or, more likely, dilutive equity financing at potentially unfavorable terms.